key: cord-0868164-4iqmi6qp
authors: Kaufman, Harvey W.; Bull-Otterson, Lara; Meyer, William A.; Huang, Xiaohua; Doshani, Mona; Thompson, William W.; Osinubi, Ademola; Khan, Mohammed A.; Harris, Aaron; Gupta, Neil; Van Handel, Michelle; Wester, Carolyn; Mermin, Jonathan; Nelson, Noele P.
title: Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic
date: 2021-05-10
journal: Am J Prev Med
DOI: 10.1016/j.amepre.2021.03.011
sha: 87ef117a85f3130b98a508a142117bf63177808d
doc_id: 868164
cord_uid: 4iqmi6qp

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic has disrupted healthcare services, reducing opportunities to conduct routine hepatitis C virus (HCV) antibody screening, clinical care, and treatment. Therefore, people living with undiagnosed HCV during the pandemic may later become identified at more advanced stages of the disease, leading to higher rates of morbidity and mortality rates. Further, unidentified HCV-infected individuals may continue to unknowingly transmit the virus to others. METHODS: To assess the impact of the COVID-19 pandemic, data were evaluated from a large national reference clinical laboratory and national estimates of dispensed prescriptions for HCV treatment. Investigators estimated the average number of HCV antibody tests, HCV antibody positive test results, and HCV RNA positive test results by month, January–July for 2018/2019, compared with the same months in 2020. To assess the impact of HCV treatment, dispensed HCV direct acting antiretroviral medications were examined for the same time periods. Statistical analyses of trends were performed using negative binomial models. RESULTS: Compared with the 2018/2019 months, HCV antibody testing volume decreased 59% during April 2020 and rebounded to a 6% reduction in July. The number of HCV RNA positive results fell by 62% in March 2020 and remained 39% below the baseline by July 2020. For HCV treatment, prescriptions decreased 43% in May, 37% in June, and 38% July relative to corresponding months in 2018/2019. CONCLUSIONS: During the COVID-19 pandemic, continued public health messaging, interventions and outreach programs to restore HCV testing and treatment to pre-pandemic levels, and maintenance of public health efforts to eliminate hepatitis C infections remain important.

Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the U.S. and is a leading cause of liver-related morbidity and mortality. 1,2 An estimated 2.4 million adults are living with HCV infection in the U.S., and hepatitis C was reported as the underlying or contributing cause for 15,713 deaths in 2018. 1 Approximately 70% of adults with acute HCV develop chronic HCV infection, and if untreated, 1 in 4 of these individuals will die prematurely from HCV-associated complications such as liver failure and hepatocellular carcinoma. 2 During 2015-2018, only 61% (95% CI=46%, 74%) of people diagnosed with hepatitis C reported having ever been told they were infected, suggesting a gap in care. 3 Healthcare screenings are essential for early identification of disease before severe morbidity or mortality occur. Hepatitis C testing is the first step in linking people with HCV infection to care and curative treatment. In 2012, the Centers for Disease Control and Prevention (CDC) recommended a 1-time HCV antibody test for all individuals born during 1945-1965 ("baby boomers"). 4 In 2013, the U.S. Preventive Services Task Force followed with recommendations for hepatitis C testing of those at high risk for infection, such as injection drug users, and a 1time test for all adults born during 1945-1965. 5 More recently, in response to increasing rates of acute HCV among young adults, including reproductive-aged people, USPSTF recommends screening for HCV infection in adults (including pregnant women) aged 18-79 years, 6 and CDC recommends hepatitis C testing at least once per lifetime, in settings with prevalence of HCV infection of ≥0.1%, for all adults aged ≥18 years and for all pregnant women during each pregnancy. 7 Fortunately, an effective and curative treatment is available. 8 Direct-acting antiretroviral (DAA) therapies, first introduced in 2013, have improved hepatitis C treatment success and reduced adverse drug events relative to interferon therapies. 10 Improvements have also been observed in the cascade of care among patients when restrictions to effective pharmaceuticals based on risk behavioral profiles have been removed. As a result, WHO established ambitious targets for hepatitis C elimination by 2030. 11 During 2020, the coronavirus disease 2019 (COVID-19) pandemic has impacted the practice of medicine. 12, 13 CDC released guidance on delaying non-essential procedures and postponing routine clinical visits as part of initial mitigation strategies for the COVID-19 pandemic. 14 As part of this guidance, patients have been advised to utilize telemedicine, patient portals, phone, and e-mail for communication with their healthcare provider and to limit in-person visits. 15 Deferral of healthcare services during the pandemic may lead to delays in diagnosis and treatment, leaving people living with hepatitis C unaware of their disease status and vulnerable to progression to advanced liver disease, including cirrhosis and hepatocellular carcinoma, as well as potential spread of the virus. 16 Changes are examined in provided healthcare services during the COVID-19 pandemic relative to prior years with a focus upon HCV antibody testing and positivity, HCV RNA positivity, and hepatitis C drug treatment prescriptions.

Clinical laboratory results were extracted from the database of Quest Diagnostics, a large clinical laboratory test provider throughout the U.S. De-identified person-level data from HCV antibody immunoassay testing and RNA diagnostic tests ordered January 1, 2018-August 8, 2020, were included. Patient age and sex were included in the analysis, when available. Data extracted from Quest Diagnostics were determined not to be individually identifiable.

All specimens with positive antibody test results reflex to HCV RNA quantitative testing used to diagnose current infection. HCV qualitative IgG antibody testing was performed using the U.S. 

For each year, 2018-2020, the total number of HCV antibody tests, HCV antibody positive test results, and HCV RNA positive test results were calculated by month from January through July.

All specimens that produced an HCV antibody positive test result were reflexed to RNA testing.

The average number of HCV antibody tests, HCV antibody positive test results, and HCV RNA positive tests and positive results was calculated by month from January through July for 2018 and 2019 to compare with the same time during 2020. Percentage change was calculated by month between the 2018/2019 monthly average and the corresponding month in 2020. For the HCV antibody tests, comparison was provided by week for the same period, January-July, to provide temporal granularity. Repeat laboratory testing within a calendar month were highly unlikely and such duplicate events were not excluded. This activity was determined by CDC to be research as defined in 46.102(l) but did not involve human subjects as defined in 46.102(e)(1)(ii).

To evaluate the impact of the pandemic on hepatitis C treatment prescriptions, hepatitis C DAA medications (Appendix 1) dispensed January 2018-July 2020 were examined. New and refilled pharmacy transactions from IQVIA National Prescription Audit® Extended Insights database include outpatient medications dispensed through retail pharmacies, mail order prescriptions, and the vast majority of prescriptions dispensed in pharmacies serving long-term care facilities. The IQVIA pharmacy transaction data were estimated to cover 92% of all outpatient retail prescription fills and 78% of all mail order prescription fills in all 50 U.S. states and the District of Columbia, and were weighted to be nationally representative of all dispensed prescriptions in these channels. The total volume of dispensed prescriptions included new and refilled prescriptions.

For each year, 2018-2020, the total number of dispensed prescriptions was calculated by month, January-July. The average number of dispensed prescriptions was also estimated by month, January-July, for 2018/2019 to compare with the same time in 2020. Percentage change was calculated by month, January-July, between the 2018/2019 monthly average and the corresponding month in 2020. Multiple prescriptions within a calendar month were not excluded as these would be unlikely events.

Trends in all outcomes were tested for deviations in counts that occurred during the pandemic period. For the weekly HCV antibody test counts, negative binomial models were used and included terms for year, week, and pandemic period. For the monthly outcomes, negative binomial models were used that included terms for year, month, and pandemic period. All statistical analyses were performed using SAS, version 9.4.

The analysis included 12,309,475 HCV antibody test results and 326,603 HCV RNA test results.

Limiting HCV antibody testing to March-July for 2018-2020, the study included 5,587,943 results ( Table 1) 

Reduction in hepatitis C testing and treatment during the COVID-19 pandemic has the potential to increase HCV-associated morbidity and mortality. Much of the focus of hepatitis C testing efforts has been in emergency department and primary care settings. 16 During the early months of the COVID-19 pandemic, most non-urgent healthcare was suspended or delayed, and emergency department visits decreased. 17 Although rates of outpatient visits started to decline in mid-March and began to increase again in May 2020, they remained substantially below prepandemic numbers from 2018/2019. 14, 18 The level of hepatitis C virus antibody testing substantially declined and that nearly returned to pre-pandemic levels by late July. On the other hand, HCV antibody positive results, HCV RNA positive results, and prescriptions dispensed did not return to pre-pandemic levels and continued to be low relative to 2018/2019 measures. This sharper decline in HCV antibody positive and RNA positive results compared with HCV antibody testing in June/July suggests many patients who returned for testing in June/July might have been lower-risk individuals, implying a potential significant gap in higher-risk patients.

Supporting these findings, a study reported that declines in HCV antibody testing and new patient identification declined fell sharply in the 3.5 months after March 16, 2020. 19 Hospitalwide testing and new patient identification fell by 49.6% and 42.1%, respectively. As expected, ambulatory-only testing and new patient identification fell more sharply, by 71.9% and 63.3%.

receipt of curative treatment will increase potential transmission of HCV infection to others and, in the long term, increase the risk of disease progression of untreated individuals. 16 Patients with advanced liver disease due to HCV infection are at risk for death and frequently need hepatic transplantation; however, effective antiviral therapy can avert these severe outcomes. 20 Future studies could examine how many patients who likely miss screening opportunities during the pandemic will develop HCV-associated complications including advanced liver disease, liver failure, need for liver transplantation, or liver cancer.

A delay is expected between hepatitis C diagnosis (i.e., a positive HCV RNA result) and subsequent HCV antiviral treatment administration. 21 The reduction in prescriptions may have continued beyond the time that HCV screening has returned to near previous levels owing to the time for patient referral to specialists and appointment scheduling, prescription authorization, and patient delays in seeking and obtaining appointments and authorizations. 22 Factors influencing prescription administration delays include insurance coverage, 23,24 racial and ethnic disparities, 25, 26 and substance use. 27 Nevertheless, delays in diagnosis may result in significant delays in treatments. The lower number of HCV diagnoses (HCV RNA positive test results) during the pandemic, extending at least through July 2020, may result in extended decreases in prescribed treatments. Further study is needed to evaluate the duration of the declines noted in this study and health disparities, particularly for those in historically underserved communities with more limited access to healthcare. Also worthy of study is how much the role of telemedicine during the pandemic has affected patients obtaining prescriptions, including the duration of each treatment prescription/refill.

An important observation is that over time the laboratory testing and treatment is shifting toward younger patients, aged 20-39 years (i.e., those born 1980 through 2000), born after the baby boomer birth cohort. This shift toward younger patients pre-dates recent changes in HCV testing guidelines 7, 8 and likely reflects greater awareness of both the known risk behaviors associated with HCV acquisition and the recent injection opioid epidemic among young adults.

Nevertheless, the shift toward younger adult patients for both testing and treatment is extremely encouraging in that the new guidelines are targeted largely at younger age groups.

Groups with high prevalence of chronic HCV infection, including people with substance use disorder who inject drugs, people with HIV, and incarcerated populations, are also likely to be severely affected by the COVID-19 pandemic and disruptions in the continuum of care given the already existing challenges with linkage to care for these vulnerable populations. [28] [29] [30] Key factors contributing to patients missing appropriate medical care during the pandemic include type of employment, (e.g., lower-wage jobs and lost employment), 31 living circumstances, (e.g., population and household density and inability to work from home), and reduced access to healthcare services, 32 factors disproportionately affecting non-Hispanic Black and Hispanic communities. 33 This evidence suggests the need to expand HCV treatment with DAAs to populations at risk for adverse outcomes, such as those with lower socioeconomic means.

Volume of HCV antibody testing was evaluated at a national level; sub-analyses on testing in specific populations were not conducted. However, based on national surveys and assessments, HCV testing trends among groups with high hepatitis C prevalence, such as people with substance use disorder who inject drugs, people born during 1945-1965 (baby boomers), and non-Hispanic Black individuals, likely follow the national testing trends. 25 People with substance use disorder who inject drugs are further impacted by a decrease in syringe service providers, including HCV testing, harm reduction (e.g., sterile inject equipment), and linkage to care services (e.g., curative treatment). 26 In addition, continued vigilance is needed in testing people born during 1945-1965, who are at the highest risk for dying of hepatitis C-related causes owing to increasing likelihood of having had HCV infection for a longer time. Lack of hepatitis C testing and treatment also has the risk of further widening racial/ethnic disparities and further impacting non-Hispanic Black and American Indian/Alaska Native populations, which are both disproportionately impacted by the COVID-19 pandemic. 31, 32 Thus, decreases in testing and treatment in vulnerable communities and among those with high hepatitis C prevalence has the risk of increasing HCV transmission among untreated people unaware of their status, further increasing hepatitis C incidence and prevalence in the U.S. and moving us further from the hepatitis C elimination goals.

There were several strengths of this study, including: (1) distinctive yet complementary views of data from clinical laboratory testing and prescription data and (2) pandemic that may have severe consequences for those with hepatitis C and those at risk of infection (e.g., exposure to virus through contact with people who are undiagnosed or untreated).

Healthcare systems design should consider new approaches that carefully balance public health strategies that deploy limited resources wisely. 36, 37 This should involve improved access to healthcare services especially among those who are uninsured and underinsured, community engagement and outreach, and expansion of telemedicine, including safe laboratory testing options. Generally speaking, healthcare systems should focus on both the COVID-19 pandemic and the unintended consequences of delayed diagnosis and treatment for other non-COVID-19

diseases. This may include developing novel public health messaging, interventions, and outreach programs for specific populations that may have lost access to effective prevention programs designed to detect and cure diseases earlier stages.

The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

HWK, WM III, and XH are employees of and own stock in Quest Diagnostics. No other financial disclosures were reported by the authors of this paper.

Viral hepatitis surveillance-United States

Prevalence of spontaneous clearance of hepatitis C virus infection doubled from 1998 to 2017

Vital signs: newly reported acute and chronic hepatitis C cases -United States

Sustained virologic response to direct-acting antiviral agents predict better outcomes in hepatitis C virus-infected patients: a retrospective study

Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965

Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement

Preventative Services Task Force. Hepatitis C virus infection in adolescents and adults: screening: United States Preventative Services Task Force statement

CDC recommendations for hepatitis C screening among adults -United States

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic hepatitis C virus without cirrhosis

Sofosbuvir for previously untreated chronic hepatitis C infection

Global policy report on the prevention and control of viral hepatitis in WHO member states

The untold toll: the pandemic's effects on patients without COVID-19

Delay or avoidance of medical care because of COVID-19-related concerns -United States

Healthcare Facilities: Managing Operations During the COVID-19 Pandemic

Impact of delayed diagnosis time in estimating progression rates to hepatitis C virus-related cirrhosis and death

Diagnosis and management of hepatitis C infection in primary care settings

As outpatient visits rebound, COVID-19 pandemic's threat to outpatient care remains

Impact of the COVID-19 pandemic on emergency department visits -United States

Impact of the 2020 COVID-19 pandemic on ambulatory hepatitis C testing

Hepatitis C-related hepatocellular carcinoma incidence in the Veterans Health Administration after introduction of directacting antivirals

Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients

Low uptake of direct-acting antiviral therapy among hepatitis C patients with advanced liver disease and access to care

Disparities in absolute denial of modern hepatitis C therapy by type of insurance

Disparities in initiation of direct-acting antiviral agents for hepatitis C virus infection in an insured population

COVID-19 and racial/ethnic disparities

Disparities in SARS-CoV-2 positivity rates: associations with race and ethnicity

Des Jariais DC. The impact of COVID-19 on syringe services programs in the United States

Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic

Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: a systematic review

Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review

Bad jobs, bad health? How work and working conditions contribute to health disparities

Unequal treatment: confronting racial and ethnic disparities in health care

COVID-19 and racial/ethnic disparities in health risk, employment, and household composition

Viral Hepatitis Surveillance Report 2018 -Hepatitis C

Improving access to the treatment of hepatitis C in low-and middle-income countries: evaluation of a patient assistance programme

The uses of adversity: leveraging the COVID-19 response to eliminate viral hepatitis

Notes: Sporadic dips reflect national holiday weeks. The MMWR week is the week of the epidemiologic year for which the National Notifiable Diseases Surveillance System (NNDSS) disease report is assigned by the reporting local or state health department for the purposes of MMWR disease incidence reporting and publishing. Values for MMWR week range

HCV, Hepatitis C virus; RNA, ribonucleic acid.